The overall aim of the project is to explore the genome-wide multi-omic alterations contributing to the biology of hematological malignancies with a focus on (but not restricted to) T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). The results from this project aims to ultimately support personalized treatment by improved risk classification and identification of novel targets for treatment. For this project we will use 1) publicly available large-scale multi-omics data including genome wide sequencing data from patients with hematological malignancies and controls; 2) perform functional analysis of cell cultures at different stages during the immortalization process.  Specific aims are to analyse: • The interplay between epigenetic alterations, genomic aberrations, transcriptome, in hematological malignanices. • Identify prognostic biomarkers and biological subgroups by multi-omic or methylation profiling • Identify potential new targets for treatment•